Clot-busting drug alteplase shows promise for stroke treatment up to 24 hours after onset

The company will use the investment proceeds to develop next-generation RNA platforms. Credit: FOTOGRIN / Shutterstock. Rona Therapeutics has secured $35m in its Series A+

The Phase II trial failed to meet its primary endpoint of change in the mean Crohn’s disease activity index (CDAI) score from baseline to week

No­vo Nordisk bol­stered its heart dis­ease da­ta for semaglu­tide on Fri­day with ad­di­tion­al analy­ses from a hand­ful of tri­als. In a pooled analy­sis of cer­tain